Intravenous gamma-globulin therapy improves hypercytokinemia in the acute phase of Kawasaki disease

Modern Rheumatology

Volumn 14, Issue 6, 2004, Pages 447-452

  Kobayashi, Naoki ^a   Mori, Masaaki ^a   Kobayashi, Yoshinori ^a   Miyamae, Takako ^a   Imagawa, Tomoyuki ^a   Okuyama, Toshiya ^b   Kurozumi, Hiroko ^c   Yokota, Shumpei ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b Saiseikai Yokohama shi Nambu Hosp   (Japan)

^c Yokohama Minami Kyosai Hospital   (Japan)

Author keywords

Hypercytokinemia; Interleukin (IL) 6; Intravenous gamma globulin (IVGG); Proinflammatory cytokine; Tumor necrosis factor (TNF) alpha

Indexed keywords

ACETYLSALICYLIC ACID; CYTOKINE; CYTOKINE RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; HUMAN; HYPERCYTOKINEMIA; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

EID: 11144338886     PISSN: 14397595     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10165-004-0341-2     Document Type: Article

References (25)

1. Kato H, Ichinose E, Yoshioka F, Takechi T, Matsunaga S, Suzuki K, et al. Fate of coronary aneurysms in Kawasaki disease: Serial coronary angiography and long-term follow-up study. Am J Cardiol 1982;49:1758-66.
2. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996;94:1379-85.
3. Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 1990;56:29-36.
4. Hirao J, Hibi S, Andoh T, Ichimura T. High levels of circulating interleukin-4 and interleukin-10 in Kawasaki disease. Int Arch Allergy Immunol 1997;112:152-6.
5. Kim DS. Serum interleukin-6 in Kawasaki disease. Yonsei Med J 1992;33:183-8.
6. Furukawa S, Matsubara T, Yone K, Hirano Y, Okumura K, Yabuta K. Kawasaki disease differs from anaphylactoid purpura and measles with regard to tumour necrosis factor-alpha and interleukin 6 in serum. Eur J Pediatr 1992;151:44-7.
7. Leung DY, Cotran RS, Kurt-Jones E, Burns JC, Newburger JW, Pober JS. Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 1989;2:1298-302.
8. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: A metaanalysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995;96:1057-61.
9. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997;131:888-93.
10. Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr 2000;137:177-80.
11. Kohsaki F. [Kawasaki disease: Diagnostic criteria.] Nippon Rinsho 1983;41:2005-7.
12. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-55.
13. Shulman ST. IVGG therapy in Kawasaki disease: Mechanism(s) of action. Clin Immunol Immunopathol. 1989;53:S141-6.
14. Leung DY. The potential role of cytokine-mediated vascular endothelial activation in the pathogenesis of Kawasaki disease. Acta Paediatr Jpn 1991;33:739-44.
15. Sakata K, Kita M, Imanishi J, Onuuchi Z, Liu Y, Mitsui Y. Effect of Kawasaki disease on migration of human umbilical vein endothelial cells. Pediatr Res 1995;38:501-5.
16. Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin: One possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994;139:5-19.
17. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-55.
18. Sato N, Sagawa K, Sasaguri Y, Inoue O, Kato H. Immunopathology and cytokine detection in the skin lesions of patients with Kawasaki disease. J Pediatr 1993;122:198-203.
19. Leung DY. Immunomodulation by intravenous immune globulin in Kawasaki disease. J Allergy Clin Immunol 1989;84:588-94.
20. Suzuki H, Uemura S, Tone S, Iizuka T, Koike M, Hirayama K, et al. Effects of immunoglobulin and gamma-interferon on the production of tumour necrosis factor-alpha and interleukin-1-beta by peripheral blood monocytes in the acute phase of Kawasaki disease. Eur J Pediatr 1996;155:291-6.
21. Lindstein T, June CH, Ledbetter JA, Stella G, Thompson CB. Regulation of lymphokine messenger RNA stability by a surfacemediated T cell activation pathway. Science 1989;244:339-43.
22. Fraser JD, Irving BA, Crabtree GR, Weiss A. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 1991;251:313-6.
23. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor: Mechanisms of production and implications in disease. FASEB J 2001;15:43-58.
24. Bauer J, Bauer TM, Kalb T, Taga T, Lengyel G, Hirano T, et al. Regulation of interleukin 6 receptor expression in human monocytes and monocyte-derived macrophages. J Exp Med 1989;170: 1537-49.
25. Furukawa S, Matsubara T, Umezawa Y, Okumura K, Yabuta K. Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease. J Pediatr 1994;124:721-5.